IFB Industries

The Washing Machine in the Corner

Look into the utility area of a middle-class Indian flat and you may well find an IFB front-load washing machine humming away, quietly doing work that a generation ago fell to aching wrists and a stone slab. That machine is the everyday face of this company. But there is a second face, hidden from the homemaker entirely — a workshop that stamps precision metal parts, called fine blanks, that go into the two-wheelers, cars and trucks passing on the road outside. One business you can see spinning in your bathroom; the other you would never notice, though it sits inside half the vehicles you ride in. IFB Industries is both at once, and that dual nature is where the interest lies.

A Company That Grew Without Asking You for More Money

Let me begin with the figure I always hunt for first, because it separates honest compounders from the crowd that mistakes your wallet for their capital. IFB's equity capital has stood at ₹41 crore in every single year from March 2015 to March 2026. Not a rupee of dilution. In a market where promoters routinely print fresh shares to paper over their ambitions, a company that funds a decade of growth without diluting the owner deserves a respectful nod. The gains, such as they are, have been shared among the same set of holders throughout.

And the growth has been real, not cosmetic. Sales climbed from ₹1,262 crore in 2015 to ₹5,666 crore over the trailing twelve months — compounded near 14% over ten years and 15% over five. That is a firm genuinely selling more machines and more metal parts each year, not one massaging its accounts. The recent pace has cooled a touch — roughly 10% over three years, 13% in the latest reading — but the trajectory remains upward and unbroken.

Promoters hold 74.96%, unchanged, and have neither trimmed nor topped up. Domestic institutions have quietly raised their stake from 4.43% to 6.15%. The smart money is nibbling, not fleeing.

Weighing the Price Against Its Own History

Here is the argument for looking now rather than later. The stock trades at a P/E of 35. That sounds far from cheap in absolute terms — and I will not pretend otherwise. But the market has, for years, been willing to pay a great deal more for this same business. Against its five-year median P/E of 69.4, today's price sits at roughly a 50% discount; against the ten-year median of 54, about a 35% discount. The crowd once voted this a glamour stock; it is now weighing it more soberly. The price has fallen from a high of ₹2,025 to ₹1,350, and grown a mere 7% over the past year while the earnings underneath have marched ahead.

Why the gap between price and past enthusiasm? Because profits here have been a lumpy, unreliable affair. Cast your eye down the record: ₹50 crore in 2015, then a slump, a recovery, a fresh slump to an outright loss of ₹51 crore in March 2022, and only lately a proper turn — ₹69 crore, ₹129 crore, ₹133 crore, and ₹146 crore trailing. Return on capital employed now stands at a respectable 18.2%, return on equity at 14.5%. The recent 98% three-year profit CAGR flatters, precisely because it is measured from the ashes of that loss.

So the story is not "buy a wonderful business cheap." It is subtler: buy a decent, debt-reduced business at a fraction of the valuation the market itself once assigned it, while its earnings power is at last showing steadiness rather than seizures. That is a margin of safety of the ordinary kind — paid for by a market that has grown wary of past disappointments.

Where I Would Keep My Guard Up

Honesty compels several cautions. First, the company pays no dividend at all — none, despite now reporting consistent profits. A shareholder is asked to trust that retained earnings compound better inside than in his own hands; the ten-year ROE of just 8% suggests that trust has not always been rewarded. Second, this is a consumer-durables maker exposed to input-cost swings and fickle discretionary demand; a monsoon-dampened festive season can undo a good year. Third, at 35 times earnings, you are not buying at a distressed price — much of your return depends on the earnings recovery *continuing*, not merely surviving.

The Verdict

I would treat IFB as a reasonable, not a table-thumping, proposition for the patient holder over one to three years. What earns it a place is the combination of a decade of undiluted, genuinely growing sales, improving returns on capital, retreating debt, and a valuation trading at half the multiple the market once thought fair. What holds me back from enthusiasm is the erratic profit history and the stubborn refusal to reward owners with a dividend. Buy modestly, insist on the discount to its own record as your cushion, and let the weighing machine do its slow work.